Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
|Videos|November 10, 2014
AZD9291 in Advanced NSCLC
Author(s)Susan Galbraith, MD, PhD
Susan Galbraith, MD, PhD, provides an overview of the ongoing phase I/II AURA study.
Advertisement
Clinical Pearls
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, provides an overview of the ongoing phase I/II AURA study, which aims to evaluate AZD9291 for patients previously treated with an EGFR TKI with advanced non-small cell lung cancer (NSCLC) with the T790M mutation.
- The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291.
- Responses are durable – median PFS is 9.6 months. Today, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.
- AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.
Advertisement
Related to this article
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5